Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States

Abstract

This analysis examined trends in incidence and survival among US adults with myeloproliferative neoplasms, including essential thrombocythemia (ET; n = 14,676), polycythemia vera (PV; n = 15,141), and primary myelofibrosis (PMF; n = 4214), using Surveillance, Epidemiology, and End User Results (SEER) data (SEER 18; 2002–2016). Incidence and survival rates over the study period and by diagnosis year (per 5-year time frames: 2002–2006; 2007–2011; 2012–2016) were assessed. The overall incidence rates (95% CI) were 1.55 (1.52–1.57) for ET, 1.57 (1.55–1.60) for PV, and 0.44 (0.43–0.45) per 100,000 person-years for PMF, with rising ET incidence. Five-year mortality over the study period was 19.2%, 19.0%, and 51.0% for ET, PV, and PMF, respectively. Improved survival over time was observed for PV and PMF, but not for ET. These findings highlight the need for effective ET therapies, as ET incidence has risen without concurrent improvements in survival over the past 2 decades.

Keywords:

• Essential thrombocythemia
• incidence
• myeloproliferative neoplasms
• polycythemia vera
• primary myelofibrosis
• survival

Acknowledgments

Writing assistance was provided by Jane Kovalevich, PhD, an employee of ICON (North Wales, PA, USA), and was funded by Incyte Corporation (Wilmington, DE, USA).

Disclosure statement

SVerstovsek received research support from AstraZeneca, Blueprint Medicines Corp., Celgene, CTI BioPharma Corp., Genentech, Gilead, Incyte Corporation, ItalPharma, Novartis, NS Pharma, PharmaEssentia, Promedior, Protagonist Therapeutics, Roche, and Sierra Oncology, and is a paid consultant for Celgene, Incyte Corporation, Novartis, and Sierra Oncology. JY, RMS, and SP are employees and shareholders of Incyte Corporation. SVerma and CD are employees of STATinMED Research, which is a paid consultant of Incyte Corporation. C-CC was an employee of STATinMED Research, which is a paid consultant of Incyte Corporation, at the time of the analysis.

Data availability statement

Access to individual patient-level data is not available for this study. Information on Incyte’s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at: https://www.incyte.com/Portals/0/Assets/Compliance%20and%20Transparency/clinical-trial-data-sharing.pdf?ver=2020-05-21-132838-960

Additional information

Funding

This work was supported by Incyte Corporation (Wilmington, DE, USA).